PT003/#255 Clinical outcomes with trastuzumab emtansine or ipatasertib plus paclitaxel for persistent/recurrent rare epithelial ovarian carcinomas: ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed study | Publicación